Analyst Reports

English reports

 
Analysguiden
 
27 Nov 2023 | Analysguiden - New strategy evolving

15 Mar 2023 | Analysguiden - Ever-changing landscape

18 Nov 2022 | Analysguiden - Promising long-term data

13 Jun 2022 | Analyseguiden - Preparing for the final

8 Mar 2022 | Analysguiden - A moving target

9 Dec 2021 | Analysguiden - Solid data open for final phase

19 Nov 2021 | Analysguiden - Phase 2 data pending

23 Aug 2021 | Analysguiden - Funding still pending

22 Apr 2021 | Analysguiden - First human data reassuring

27 Jan 2021 | Analysguiden - Getting Close To Patients

3 Sep 2020 | Analysguiden - Broadening the Portfolio

21 Nov 2019 | Analysguiden - Potential at Reduced Risk

 
Pareto Securities
 

17 August 2023 | Pareto - Evaluating BC strategic options (Newsflash)

27 June 2023 Pareto | ABNCoV2 phase II meets primary endpoint (Newsflash)

16 June 2023 Pareto | ABNCoV2 strong durability data (Newsflash)

16 May 2023 Pareto | 2023 Q1 Report (Newsflash)

18 April 2023 Pareto | Initial gross proceeds of SEK 54.5m

6 March 2023 Pareto | 2023 Right Issue Announcement

3 March 2023 Pareto | Mucosal Vaccine

9 February 2023 Pareto | 2022 YE Report Newsflash

6 December 2022 Pareto | Evaxion CMV vaccine collaboration Newsflash

17 November 2022 Pareto | 9M 2022 Report Newsflash

24 Oct 2022 Pareto | ES2B-C001 positive preclinical data published

18 Oct 2022 Pareto | ABNCoV2 reports positive phase II durability data

22 Sep 2022 Pareto | COVID vaccine phase III trial ongoing

8 Apr 2022 Pareto | Cash position to be further increased

1 Mar 2022 Pareto | Further progress with COVID-19 vaccine

10 Jan 2022 Pareto | Exciting topline preclinical results for ES2B-C001

7 Dec 2021 | Pareto - Great ABNCoV2 Phase II top line results

17 Nov 2021 | Pareto - COVID-19 vaccine Phase II readout on the horizon

20 Aug 2021 | Pareto - Initiation of Phase II trial just around the corner

9 Aug 2021 | Pareto - Great COUGH-1 headline results

24 Jun 2021 | Pareto - Rights to COVID-19 Challenge (Initiation)